comparemela.com

Latest Breaking News On - Natco pharma - Page 5 : comparemela.com

Stock Radar: Aurobindo, Adani Ports, RVNL, NTPC, Torrent Pharma, Divis Labs, Glenmark in focus on Monday

More than 300 companies will release their quarterly earnings on May 27 including Life Insurance Corporation of India, Astrazeneca Pharma, Borosil Renewables, Flair Writing Industries, Jubilant Industries, Natco Pharma, and NALCO.

India
Canara
Karnataka
Nagpur
Maharashtra
Calcutta
West-bengal
United-states
Cochin
Kerala
Telangana
Andhra-pradesh

Share Market Highlights 15 May 2024: Sensex, Nifty edge down; Coal India spikes up 4%

Share Market Highlights 15 May 2024: Sensex, Nifty edge down; Coal India spikes up 4%
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Ireland
Andhra
Andhra-pradesh
India
Sandur
Karnataka
Israel
Jamna
Ivano-frankivs-ka-oblast
Ukraine
Helgi
Sakha-yakutiya

Healthtech's latest buzzword is a relentless killer

Healthtech's latest buzzword is a relentless killer
livemint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livemint.com Daily Mail and Mail on Sunday newspapers.

Alabama
United-states
Yelahanka
Karnataka
India
Ranchi
Jharkhand
Cuttack
Orissa
Hyderabad
Andhra-pradesh
Delhi

Veeda Clinical Research: CX Partners-led consortium looks to sell majority stake, eyes $600 mn -$650 mn valuation

In December 2018, a consortium of growth-oriented private equity firms led by CX Partners acquired a significant equity ownership in Veeda.

India
United-kingdom
Brazil
Arjun-bhartia
Natco-pharma
Nikhil-vora
Pranab-mody
Bioneeds-india-private
Veeda-clinical-research
Dr-mahesh-bhalgat-as-group
Indian-bank
Ujjivan-financial-services

Hot Stocks: Brokerages on RIL, Entero Healthcare, Natco Pharma and Persistent Systems

Brokerage Nomura upheld a neutral rating on Persistent Systems, while Investec continues to advocate a buy stance on Natco Pharma and has initiated a buy recommendation on Entero Healthcare. Conversely, CLSA has downgraded RIL to an outperform rating.

Natco-pharma
Brokerage-nomura
Persistent-systems
Entero-healthcare

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.